Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 0.50 |
| ▸ | HTR2B | P41595 | 13/20 | 0.50 |
| ▸ | HTR2A | P28223 | 12/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4432187 | 0.83 | HTR2C (0.46) | HTR2CHTR2BHTR2ATAAR1 | |
| SCHEMBL4434039 | 0.81 | HTR2C (0.53) | HTR2CHTR2BHTR2ATAAR1 | |
| SCHEMBL6446140 | 0.76 | HTR2C (0.50) | HTR2CHTR2BHTR2ATAAR1 | |
| SCHEMBL2404066 | 0.74 | HTR2C (0.54) | HTR2CHTR2BHTR2A | |
| SCHEMBL1024269 | 0.71 | HTR2C (0.43) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL224424 | 0.70 | HTR2C (0.42) | HTR2CHTR2BHTR2A | |
| SCHEMBL3558907 | 0.69 | HTR2C (0.54) | HTR2CHTR2BHTR2ATAAR1CHRNB2 | |
| SCHEMBL3558442 | 0.69 | HTR2C (0.54) | HTR2CHTR2BHTR2ATAAR1CHRNB2 | |
| SCHEMBL4430749 | 0.68 | HTR2C (0.49) | HTR2CHTR2BHTR2A | |
| SCHEMBL2514720 | 0.67 | HTR2C (0.81) | HTR2CCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HTR2C 3663/4885HTR2B 3637/4885HTR2A 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.